Nxera Pharma Licenses IBD Drug Candidate to AbbVie
Nxera will receive US$100 million upfront and is eligible for up to US$1.37 billion in development and other milestone payments under a global license agreement with AbbVie.
Story updates
08:44:33 AM UTC
SquawkNews
NXERA PHARMA CO. - $100 MLN UPFRONT PAYMENT EXPECTED TO BE RECOGNIZED AS REVENUE IN Q4 FY2026
08:46:42 AM UTC
SquawkNews
Tokyo, Japan and Cambridge, UK, 4 November 2026 — Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharma UK Ltd, has entered into an exclusive global license agreement (the “Agreement”) with AbbVie Inc. (“AbbVie”) for Nxera’s EP4 agonist progr…